| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | CA2365341A1 C-terminal modified (n-substituted)-2-indolylcarbonyldipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/03/2001 | EP1065210A1 Novel xanthone compounds, their preparation and use as medicament |
| 01/03/2001 | EP1065209A1 Metalloprotease inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 01/03/2001 | EP1065208A1 Substituted purine derivatives as inhibitors of cell adhesion |
| 01/03/2001 | EP1065207A1 Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
| 01/03/2001 | EP1065206A1 Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents |
| 01/03/2001 | EP1065204A1 Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors |
| 01/03/2001 | EP1064967A2 5HT1 receptor agonists, caffeine and either a COX-2 inhibitor or NSAID for the treatment of migraine |
| 01/03/2001 | EP1064966A2 Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
| 01/03/2001 | EP1064965A2 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 01/03/2001 | EP1064964A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064950A1 Remedies for hepatitis |
| 01/03/2001 | EP1064949A2 Compositions containing aldose reductase inhibitors and selective cyclooxygenase inhibitors for the treatment of diabetic complications |
| 01/03/2001 | EP1064948A2 Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine |
| 01/03/2001 | EP1064946A2 Topical zinc compositions |
| 01/03/2001 | EP1064945A1 Therapeutic use of a helium/oxygen mixture, especially for treating asthma |
| 01/03/2001 | EP1064944A1 Protein kinase N inhibitor comprising Fasudil |
| 01/03/2001 | EP1064943A1 Combination having antilipemic activity substantially free from toxic or side effects due to antilipemic drugs |
| 01/03/2001 | EP1064942A1 Sustained release preparations |
| 01/03/2001 | EP1064941A1 Use of melatoninergic ligands for obtaining pharmaceutical compositions for the prevention or the treatment of gastrointestinal pathologies |
| 01/03/2001 | EP1064940A1 Antiviral therapy |
| 01/03/2001 | EP1064939A2 Transdermal systems for release of 5-HT3 receptor antagonists and use thereof for antiemetic treatment |
| 01/03/2001 | EP1064937A1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/03/2001 | EP1064936A1 Novel composition of paroxetine methanesulfonate |
| 01/03/2001 | EP1064935A1 Solid thermoformable controlled-release pharmaceutical composition |
| 01/03/2001 | EP1064404A1 P53-regulated genes |
| 01/03/2001 | EP1064403A1 Antisense modulation of pecam-1 |
| 01/03/2001 | EP1064402A1 Antisense modulation of lfa-3 |
| 01/03/2001 | EP1064388A1 Human casb12 polypeptide, a serine protease |
| 01/03/2001 | EP1064379A2 Human nucleic acid sequences from tissue of breast tumors |
| 01/03/2001 | EP1064378A2 Hypoxia-inducible human genes, proteins, and uses thereof |
| 01/03/2001 | EP1064377A1 Casb414: antigen overexpressed in several tumours |
| 01/03/2001 | EP1064372A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/03/2001 | EP1064371A2 Isolated mammalian membrane protein genes and related reagents |
| 01/03/2001 | EP1064354A1 Compositions and methods for gene-based vaccines to provoke t cell responses |
| 01/03/2001 | EP1064301A1 Bacterial yael family members as targets for antimicrobial drug design |
| 01/03/2001 | EP1064298A2 Inhibitors of caspases |
| 01/03/2001 | EP1064294A1 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them |
| 01/03/2001 | EP1064293A1 Crystallization of lactitol, crystalline lactitol product and use thereof |
| 01/03/2001 | EP1064289A1 Heterocyclic signal transduction inhibitors, compositions containing them |
| 01/03/2001 | EP1064285A1 Novel cephalotaxane derivatives and process for their preparation |
| 01/03/2001 | EP1064284A1 Hypnotic beta-carboline derivatives, process for their preparation and their use as medicinal products |
| 01/03/2001 | EP1064283A1 Pyrazolo-pyridine derivatives as ligands for gaba receptors |
| 01/03/2001 | EP1064282A1 Crystalline form of paroxetine |
| 01/03/2001 | EP1064281A1 Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor agents |
| 01/03/2001 | EP1064280A1 Acryloyl derivatives analogous to distamycin, process for preparing them, and their use as antitumor agents |
| 01/03/2001 | EP1064279A1 Substituted bisindolylmaleimides for the inhibition of cell proliferation |
| 01/03/2001 | EP1064277A1 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
| 01/03/2001 | EP1064274A1 Benzenesulfonamide derivatives and their use as medicaments |
| 01/03/2001 | EP1064273A2 1,3,4-thiadiazoles useful for the treatment of cmv infections |
| 01/03/2001 | EP1064272A1 Cyclooctadepsipeptides and their use for combating endoparasites |
| 01/03/2001 | EP1064270A2 Disubstituted pyrazolines and triazolines as factor xa inhibitors |
| 01/03/2001 | EP1064269A1 Barbituric acid derivative and preventive and therapeutic agent for bone and cartilage containing the same |
| 01/03/2001 | EP1064264A1 Cytotoxic metal chelators and methods for making and using same |
| 01/03/2001 | EP1064263A2 Nonnucleoside inhibitors of reverse transcriptase for the treatment of hiv-infection |
| 01/03/2001 | EP1064262A1 Substituted isoindolones and their use as cyclic gmp modulators in medicaments |
| 01/03/2001 | EP1064259A1 New compounds |
| 01/03/2001 | EP1064257A1 Anti-tumour agents |
| 01/03/2001 | EP1064256A1 Bicyclo [2.2.1] heptanes and related compounds |
| 01/03/2001 | EP1064254A2 Aliphatic amino carboxylic and amino phosphonic acids, amino nitriles and amino tetrazoles as cellular rescue agents |
| 01/03/2001 | EP1064253A1 Anti-tumour agents |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064023A1 Products in the treatment of cancer |
| 01/03/2001 | EP1064021A1 Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment |
| 01/03/2001 | EP1064020A1 Methods for diagnosing and treating autoimmune disease |
| 01/03/2001 | EP1064009A1 Utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as an estrogen-like organ-selective medicament without uterotropic effects |
| 01/03/2001 | EP1064004A1 Metal/thiol biocides |
| 01/03/2001 | EP1064003A1 Neurotrophic properties of ipgs and ipg analogues |
| 01/03/2001 | EP1064002A1 Use of sphingosin-1-phosphate, sphingosin-1-phosphate derivatives and/or mixtures thereof for the treatment of inflammatory diseases of the skin |
| 01/03/2001 | EP1064001A2 Methods and compositions for treating and preventing mucositis |
| 01/03/2001 | EP1064000A1 Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders |
| 01/03/2001 | EP1063999A1 Epiallopregnanolone in the treatment of cns disorders |
| 01/03/2001 | EP1063998A1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/03/2001 | EP1063997A2 Peripheral-type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 01/03/2001 | EP1063996A1 Pharmaceutical compositions containing in combination two antagonists selective of arginine-vassopressin v receptors, even of v 1a? and v 2? receptors |
| 01/03/2001 | EP1063995A1 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator |
| 01/03/2001 | EP1063994A1 Method of treating skin irritation |
| 01/03/2001 | EP1063993A1 Paroxetine compositions |
| 01/03/2001 | EP1063992A1 Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations |
| 01/03/2001 | EP1063991A1 Statin-matrix metalloproteinase inhibitor combinations |
| 01/03/2001 | EP1063990A1 Therapy of estrogen-associated disorders |
| 01/03/2001 | EP1063989A1 Prevention and treatment of adhesions |
| 01/03/2001 | EP1063988A1 Hesperidin and hesperetin as inhibitor of acyl coa-cholesterol-o-acyltransferase, inhibitor ofmacrophage-lipid complex accumulation on the arterial wall and preventive or treating agent for hepatic diseases |
| 01/03/2001 | EP1063987A1 Dietary control of arachidonic acid metabolism |
| 01/03/2001 | EP1063985A1 Benzoates derivatives for inhibiting angiogenesis |
| 01/03/2001 | EP1063984A1 Inflammatory cell inhibitors |
| 01/03/2001 | EP1063983A1 Transdermal therapeutic system (tts) containing oxybutynin |
| 01/03/2001 | EP1063982A2 Antagonists for treatment of cd11/cd18 adhesion receptor mediated disorders |
| 01/03/2001 | EP1063981A1 Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage |
| 01/03/2001 | EP1063980A2 Methods for decreasing beta amyloid protein production |
| 01/03/2001 | EP1063978A1 Method of treating neuroma pain |
| 01/03/2001 | EP1063977A1 Coated starch capsules and a process for producing them |
| 01/03/2001 | EP1063973A1 Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 01/03/2001 | EP1063971A1 Controlled release oral tablet having a unitary core |
| 01/03/2001 | EP1063969A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 01/03/2001 | EP1063968A1 Improved compositions for inhalation |
| 01/03/2001 | EP1063966A1 Methods for regulating skin appearance |
| 01/03/2001 | EP1063963A1 Method of reducing cellulite in mammalian skin |
| 01/03/2001 | EP1063886A1 Disinfecting composition |